$ONCT
Oncternal Therapeutics Inc
PRICE
$0.8401 βΌ-3.802%
Extented Hours
VOLUME
178,778
DAY RANGE
0.84 - 0.882
52 WEEK
0.5951 - 1.87
Join Discuss about ONCT with like-minded investors
@dros #droscrew
Top Earnings Th 3/9 Aft: $ACHR $AEYE $AGIL $AGS $AIRG $AKA $ALGS $ALTG $ALTO $AMPY $AOUT $APPH $AQMS $ATER $AVO $AVPT $AWRE $BBCP $BIRD $BKKT $BNGO $BWMN $CLSD $CMTL $CRIS $CTSO $DALN $DOCU $DOUG $GEVO $GHLD $GPS $GRTS $HCI $HCP $HGBL $HRT $HYFM (1/2) Top Earnings Th 3/9 Aft: $III $INUV $IRIX $JAKK $JSDA $JYNT $LCTX $LIFE $LMNR $LOCO $LRFC $LTM $MTN $MYPS $NNBR $NX $ODC $ONCT $ORCL $PAM $PTMN $QFIN $RAIN $REI $RGLS $SBIG $SMSI $STKS $TGS $TLYS $TOI $ULTA $VEL $WATT $WLDN $YPF $ZUMZ (2/2) Top Earnings Fri 3/10 Pre: $AIRS $BRDS $BKE $CNTY $CCLP $DALN $ERJ $GENI $LEV $LGVN $RAND $RLX $SDPI $TH
70 Replies 12 π 13 π₯
@maletone #StockTraders.NET
wow $ONCT tomorrow might be the day for the short
76 Replies 10 π 11 π₯
@maletone #StockTraders.NET
would be ncie if $ONCT could go higher might re hit it
60 Replies 7 π 9 π₯
@TraderXx #StockTraders.NET
$ONCT If I was shorting would cover and move on
150 Replies 7 π 15 π₯
Key Metrics
Market Cap
51.27 M
Beta
1.32
Avg. Volume
302.24 K
Shares Outstanding
58.71 M
Yield
0%
Public Float
0
Next Earnings Date
2023-05-04
Next Dividend Date
Company Information
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
CEO: James Breitmeyer
Website: www.oncternal.com
HQ: 12230 El Camino Real Ste 300 San Diego, 92130-2090 California
Related News